The epidermal growth factor receptor (EGFR) gene-activating mutations represented the first molecular predictive biomarker which was discovered in lung cancer in 2004, underlying clinical responsiveness to the EGFR tyrosine kinase inhibitors (TKIs) [6]. Here, EGFR is linked to lung carcinoma.